Exact Mass: 341.2272

Exact Mass Matches: 341.2272

Found 111 metabolites which its exact mass value is equals to given mass value 341.2272, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

LINDHEIMERINE

LINDHEIMERINE

C22H31NO2 (341.2355)


   

Pregnenolone carbonitrile

Pregnenolone carbonitrile; 3beta-Hydroxy-20-oxo-5-pregnene-16alpha-carbonitrile; Pregnenolone-16alpha-carbonitrile; PCN

C22H31NO2 (341.2355)


   

5-Hydroxymethyl tolterodine

(R)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine

C22H31NO2 (341.2355)


5-Hydroxymethyl tolterodine is only found in individuals that have used or taken tolterodine. 5-Hydroxymethyl tolterodine is a metabolite of tolterodine. 5-Hydroxymethyl tolterodine belongs to the family of Diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.

   

Diprotin A

2-({[1-(2-amino-3-methylpentanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoate

C17H31N3O4 (341.2314)


   

Pregnenolone carbonitrile

14-acetyl-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-ene-13-carbonitrile

C22H31NO2 (341.2355)


   

(8S,9S,10S,13S,14S,17S)-17-Acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-1-carbonitrile

(8S,9S,10S,13S,14S,17S)-17-Acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-1-carbonitrile

C22H31NO2 (341.2355)


   

Leu-Pro-Ile

2-({[1-(2-amino-4-methylpentanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

C17H31N3O4 (341.2314)


   

Deoxycalyciphylline B

(1S,6R,7R,10R,15S,22R)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.01,6.07,15.010,14.019,22]docos-13-en-4-one

C22H31NO2 (341.2355)


   
   

Isodaphnilactone B

Isodaphnilactone B

C22H31NO2 (341.2355)


   

Malouetamide

Con-4-enine-3,18-dione

C22H31NO2 (341.2355)


   

Daphnilactone B

(-)-Daphnilactone B

C22H31NO2 (341.2355)


   
   
   

Spirafine III

Spirafine III

C22H31NO2 (341.2355)


   

9-Methoxy-Nb-methylgeissoschizol

9-Methoxy-Nb-methylgeissoschizol

C21H29N2O2+ (341.2229)


   

Nb-Methylisoajmaline

(+)-Nb-Methylisoajmaline

C21H29N2O2 (341.2229)


   

19-methylaminoavarone|3-Methylaminoavarone

19-methylaminoavarone|3-Methylaminoavarone

C22H31NO2 (341.2355)


   

18-methylaminoavarone|2-Methylaminoavarone|3-methylaminoavarone

18-methylaminoavarone|2-Methylaminoavarone|3-methylaminoavarone

C22H31NO2 (341.2355)


   

18-methylaminoarenarone

18-methylaminoarenarone

C22H31NO2 (341.2355)


   

(E)-3,7-dimethylocta-2,6-dienyl 2-(3-methylbut-2-enylamino)benzoate|geranyl N-dimethylallylanthranilate

(E)-3,7-dimethylocta-2,6-dienyl 2-(3-methylbut-2-enylamino)benzoate|geranyl N-dimethylallylanthranilate

C22H31NO2 (341.2355)


   

dysidaminone I

dysidaminone I

C22H31NO2 (341.2355)


   

(2E,4E,10E)-N-isobutyl-11-(4-methoxyphenyl)undeca-2,4,10-trienamide|philippinamide

(2E,4E,10E)-N-isobutyl-11-(4-methoxyphenyl)undeca-2,4,10-trienamide|philippinamide

C22H31NO2 (341.2355)


   

(-)-bukittinggine

(-)-bukittinggine

C22H31NO2 (341.2355)


   

regholarrhenine|Regholarrhenine A

regholarrhenine|Regholarrhenine A

C22H31NO2 (341.2355)


   

hydroxy-3 oxo-9 seco-9,10 conatriene-1,3,5

hydroxy-3 oxo-9 seco-9,10 conatriene-1,3,5

C22H31NO2 (341.2355)


   
   
   
   
   
   

MLS002207185-01!Ile-Pro-Ile90614-48-5

MLS002207185-01!Ile-Pro-Ile90614-48-5

C17H31N3O4 (341.2314)


   
   
   
   
   
   
   
   
   
   
   
   

Diprotin A

Diprotin A

C17H31N3O4 (341.2314)


D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors Diprotin A (Ile-Pro-Ile) is an inhibitor of dipeptidyl peptidase IV (DPP-IV)[1].

   

5-Hydroxymethyltolterodine

5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)

C22H31NO2 (341.2355)


Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively[1]. Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053)[2][3]. Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats[4].

   

(Rac)-5-Hydroxymethyl Tolterodine

(Rac)-5-Hydroxymethyl Tolterodine

C22H31NO2 (341.2355)


(Rac)-5-Hydroxymethyl Tolterodine ((Rac)-Desfesoterodine), an active metabolite of Tolterodine, is a mAChR antagonist (Ki values of 2.3 nM, 2 nM, 2.5 nM, 2.8 nM, and 2.9 nM for M1, M2, M3, M4, and M5 receptors, respectively). (Rac)-5-Hydroxymethyl Tolterodine can be used for overactive bladder research[1].

   

(E)-16-(carboxymethylamino)-4-oxohexadec-11-enoic acid

(E)-16-(carboxymethylamino)-4-oxohexadec-11-enoic acid

C18H31NO5 (341.2202)


   

4-[3-(1-Imidazolyl)proplyaminomethyl]benzeneboronic acid pinacol ester

4-[3-(1-Imidazolyl)proplyaminomethyl]benzeneboronic acid pinacol ester

C19H28BN3O2 (341.2274)


   

(3-chloro-2-hydroxypropyl)dodecyldimethylammonium chloride

(3-chloro-2-hydroxypropyl)dodecyldimethylammonium chloride

C17H37Cl2NO (341.2252)


   

Tetrabutylammonium perchlorate

Tetrabutylammonium perchlorate

C16H36ClNO4 (341.2333)


   

2-di-t-butylphosphino-2-(n,n-dimethylamino)biphenyl

2-di-t-butylphosphino-2-(n,n-dimethylamino)biphenyl

C22H32NP (341.2272)


   

n-(1-Adamantyl)-n-(4-guanidinobenzyl)urea

n-(1-Adamantyl)-n-(4-guanidinobenzyl)urea

C19H27N5O (341.2215)


   

17-acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-16-carbonitrile

17-acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-16-carbonitrile

C22H31NO2 (341.2355)


   
   

Desfesoterodine

5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)

C22H31NO2 (341.2355)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively[1]. Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053)[2][3]. Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats[4].

   

2-{[1-(2-Amino-3-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoic acid

2-{[1-(2-Amino-3-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoic acid

C17H31N3O4 (341.2314)


   

Nbeta-methylajmaline

Nbeta-methylajmaline

C21H29N2O2+ (341.2229)


   
   
   

Leucyl-leucyl-proline

Leucyl-leucyl-proline

C17H31N3O4 (341.2314)


   

1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.2314)


   

1-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.2314)


   

1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.2314)


   

1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.2314)


   

1-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.2314)


   

1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.2314)


   
   
   
   
   
   
   
   
   

methylglyoxal-lysine dimer

methylglyoxal-lysine dimer

C16H29N4O4 (341.2189)


An imidazolium ion formed via cyclo-dimerisation of L-lysine and methylglyoxal.

   

NA-Asp 14:1(9Z)

NA-Asp 14:1(9Z)

C18H31NO5 (341.2202)


   
   
   

CB2R/FAAH modulator-3

CB2R/FAAH modulator-3

C22H31NO2 (341.2355)


CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The Ki values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC50 value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection[1].

   

(1s,7s,10s,11r,15r,22r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one

(1s,7s,10s,11r,15r,22r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one

C22H31NO2 (341.2355)


   

(1s,2r,3r,5s,8r,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

(1s,2r,3r,5s,8r,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

C22H31NO2 (341.2355)


   

(5z,8z,11z)-n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid

(5z,8z,11z)-n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid

C22H31NO2 (341.2355)


   

(1s,6r,7s,10r,15r,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(1s,6r,7s,10r,15r,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2355)


   

(1r,7r,10r,11s,15s,18s,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

(1r,7r,10r,11s,15s,18s,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

C22H31NO2 (341.2355)


   

(2s,3s)-2-({[(2s)-1-[(2s,3s)-2-amino-3-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

(2s,3s)-2-({[(2s)-1-[(2s,3s)-2-amino-3-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

C17H31N3O4 (341.2314)


   

(2r,3z,12bs)-3-ethylidene-2-(2-hydroxyethyl)-9-methoxy-5-methyl-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

(2r,3z,12bs)-3-ethylidene-2-(2-hydroxyethyl)-9-methoxy-5-methyl-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

[C21H29N2O2]+ (341.2229)


   

11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

C22H31NO2 (341.2355)


   

(2e,4e,10e)-11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

(2e,4e,10e)-11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

C22H31NO2 (341.2355)


   

(1s,6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(1s,6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2355)


   

(1r,7r,10r,11s,15s,18r,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

(1r,7r,10r,11s,15s,18r,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

C22H31NO2 (341.2355)


   

n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid

n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid

C22H31NO2 (341.2355)


   

(1s,2s,3s,5r,8s,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

(1s,2s,3s,5r,8s,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

C22H31NO2 (341.2355)


   

(1s,6s,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(1s,6s,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2355)


   

(1r,7r,10r,11r,15s,18r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

(1r,7r,10r,11r,15s,18r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

C22H31NO2 (341.2355)


   

2-{[(1r,2s,4as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl}-5-(methylamino)cyclohexa-2,5-diene-1,4-dione

2-{[(1r,2s,4as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl}-5-(methylamino)cyclohexa-2,5-diene-1,4-dione

C22H31NO2 (341.2355)


   

(1s,2s,5s,6s,9r,11r,12s,13r)-11-hydroxy-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

(1s,2s,5s,6s,9r,11r,12s,13r)-11-hydroxy-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C22H31NO2 (341.2355)


   

11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

C22H31NO2 (341.2355)


   

(6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2355)


   

11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

C22H31NO2 (341.2355)


   

(1r,7r,10r,14s,15s,22r)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

(1r,7r,10r,14s,15s,22r)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

C22H31NO2 (341.2355)


   

deoxyisocalyciphylline b

deoxyisocalyciphylline b

C22H31NO2 (341.2355)


   

(1r,7r,10r,11s,14r,15s,18r,22r,23s)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

(1r,7r,10r,11s,14r,15s,18r,22r,23s)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

C22H31NO2 (341.2355)


   

11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

C22H31NO2 (341.2355)


   

11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one

11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one

C22H31NO2 (341.2355)


   

2-({[1-(2-amino-3-methylpentanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

2-({[1-(2-amino-3-methylpentanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

C17H31N3O4 (341.2314)


   

(2r,3e,5s,12bs)-3-ethylidene-2-(2-hydroxyethyl)-8-methoxy-5-methyl-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

(2r,3e,5s,12bs)-3-ethylidene-2-(2-hydroxyethyl)-8-methoxy-5-methyl-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

[C21H29N2O2]+ (341.2229)


   

(1r,2s,5s,6s,9r,12s,13r)-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-17-ene-8,16-dione

(1r,2s,5s,6s,9r,12s,13r)-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-17-ene-8,16-dione

C22H31NO2 (341.2355)


   

6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2355)


   

(1s,6s,7r,10r,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(1s,6s,7r,10r,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2355)


   

11-hydroxy-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

11-hydroxy-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C22H31NO2 (341.2355)